Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
May 10, 2024 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:45 ET
|
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 12, 2024 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines to Participate in Upcoming April Conferences
April 05, 2024 09:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024 17:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
March 28, 2024 00:20 ET
|
Praxis Precision Medicines, Inc.
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
March 27, 2024 16:01 ET
|
Praxis Precision Medicines, Inc.
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 26, 2024 06:30 ET
|
Praxis Precision Medicines, Inc.
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with...
Praxis Precision Medicines to Host PRAX-628 Program Update
March 25, 2024 16:01 ET
|
Praxis Precision Medicines, Inc.
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 05, 2024 07:00 ET
|
Praxis Precision Medicines, Inc.
Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be...